SF3B1 and myelodysplastic syndrome: Thus, MDS with low blasts and SF3B1 mutation (MDS-SF3B1) is considered a separate MDS entity in both WHO 2022 [1] and ICC [2] with slightly deviating defining entity criteria (Suppl.